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Abstract
Background:  To determine the incidence of reversible amenorrhea in women with breast cancer
undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel.
Methods:  We studied the incidence and duration of amenorrhea induced by two chemotherapy
regimens: (i) 6 cycles of 5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2 and cyclophosphamide 500 mg/
m2 on day 1 every 3 weeks (6FEC) and (ii) 3 cycles of FEC 100 followed by 3 cycles of docetaxel 100 mg/
m2 on day 1 every 3 weeks (3FEC/3D). Reversible amenorrhea was defined as recovery of regular menses
and, where available (101 patients), premenopausal hormone values (luteinizing hormone (LH), follicle-
stimulating hormone (FSH) and estradiol) in the year following the end of chemotherapy.
Results: One hundred and fifty-four premenopausal patients were included: 84 treated with 6FEC and 70
with 3FEC/3D. The median age was 43.5 years (range: 28–58) in the 6FEC arm and 44 years (range: 29–
53) in the 3FEC/3D arm. Seventy-eight percent of patients were treated in the context of the PACS 01
trial. The incidence of chemotherapy-induced amenorrhea at the end of chemotherapy was similar in the
two groups: 93 % in the 6FEC arm and 92.8 % in the 3FEC/3D arm. However, in the year following the
end of chemotherapy, more patients recovered menses in the 3FEC/3D arm than in the 6FEC arm: 35.5
% versus 23.7 % (p = 0.019). Among the 101 patients for whom hormone values were available, 43 % in
the 3FEC/3D arm and 29 % in the 6FEC arm showed premenopausal levels one year after the end of
chemotherapy (p < 0.01). In the 3FEC/3D group, there was a statistically significant advantage in disease-
free survival (DFS) for patients who were still amenorrheic after one year, compared to patients who had
recovered regular menses (p = 0.0017).
Conclusion: Our study suggests that 3FEC/3D treatment induces more reversible amenorrhea than
6FEC. The clinical relevance of these findings needs to be investigated further.
Published: 21 February 2008
BMC Cancer 2008, 8:56 doi:10.1186/1471-2407-8-56
Received: 21 September 2007
Accepted: 21 February 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/56
© 2008 Berliere et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2008, 8:56 http://www.biomedcentral.com/1471-2407/8/56
Page 2 of 9
(page number not for citation purposes)
Background
Adjuvant chemotherapy prolongs disease-free and overall
survival of patients with breast cancer. In premenopausal
women, cytotoxic chemotherapy can induce temporary or
permanent ovarian dysfunction [1-4]. The incidence of
chemotherapy-induced amenorrhea is directely related to
age and varies with the type of chemotherapeutic agent
used [5,6], as well as its dose and schedule [1]. Data on
ovarian function are widely available for certain regimens,
such as cyclophosphamide, methotrexate and 5-fluorour-
acil (CMF) polychemotherapy [6,7] and anthracycline-
based treatments [8,9], but fewer studies have been con-
ducted on taxane-based regimens and they unfortunately
show contradictory results [10-13]. Here, we report the
results of a retrospective analysis evaluating the incidence
of reversible amenorrhea in women with early-stage
breast cancer undergoing adjuvant anthracycline-based
chemotherapy with or without docetaxel.
Methods
Patients and study design
Between June 1997 and March 2000, 1999 patients from
83 French and Belgian cancer centers were included in the
PACS 01 trial. This trial was designed to evaluate the
impact of the sequential addition of docetaxel to anthra-
cycline-based chemotherapy on the disease-free survival
(DFS) of patients with node-positive operable breast can-
cer [7]. The design of the study is detailed in Figure 1. The
first arm (6FEC) involved administration of 6 cycles of
FEC 100 (5-fluorouracil 500 mg/m2, epirubicin 100 mg/
m2, and cyclophosphamide 500 mg/m2) on day 1 every 3
weeks, and the second arm (3FEC/3D), administration of
3 cycles of FEC 100 followed by 3 cycles of docetaxel 100
mg/m2 on day 1 every 3 weeks.
Two Belgian centers (Cliniques Universitaires St Luc
(UCL), Brussels, and Clinique Ste Elisabeth, Namur) and
one French center (Institut Claudius Regaud, Toulouse)
retrospectively studied a number of premenopausal
patients (n = 154): 121 patients (78 %) included in the
PACS 01 trial and 33 patients (22 %) treated with the
same regimens after the PACS 01 inclusion period. These
patients were followed clinically for menses recovery
every 3 months. For 101 patients, hormone values were
also available (luteinizing hormone (LH), follicle-stimu-
lating hormone (FSH) and estradiol). A minimum of two
tests were performed at 3-monthly intervals in the year
following the end of chemotherapy.
Study of amenorrhea was not an endpoint of the PACS 01
trial. Clinicians had to report patient status (amenorrheic
or not) at the end of the study, but no follow-up of men-
opausal status was required.
In the centers (2 Belgian, 1 French) conducting the retro-
spective study, clinicians were specifically interested in
investigating amenorrhea and collected clinical and (for
101 women) biological data. Since a total of 1211 pre-
menopausal patients (598 in the 6FEC arm and 613 in the
3FEC/3D arm) were enrolled in the PACS 01 trial, our
series of 154 patients (121 from the PCAS 01 trial + 33
outside the trial) effectively represents 10 % of all premen-
opausal patients included in the PACS 01 trial.
The PACS 01 study was approved by the institutional eth-
ical committees of all the centers involved. For blood
tests, informed consent was obtained from patients in
accordance with institutional guidelines.
The main objective of our retrospective study was to eval-
uate the incidence of reversible chemotherapy-induced
amenorrhea in patients treated with 6FEC and 3FEC/3D
(impact of sequential docetaxel on the rate of chemother-
apy-related amenorrhea). Reversible amenorrhea was
defined as recovery of regular menses and, where available
(101 patients), premenopausal LH, FSH and 17-beta-
estradiol values in the year following the last chemother-
apy infusion. Premenopausal hormone concentrations
were defined by our laboratory as LH < 17.1 mIU/ml, FSH
< 45.7 mIU/ml, and 17-beta-estradiol > 50 pg/ml.
Menopausal status was defined according to World
Health Organization recommendations, which regard
amenorrhea lasting 12 months as indicative of the meno-
pause [14]. It is important to note that, in breast cancer,
criteria for identifying women as postmenopausal vary
between trials and research groups.
Statistical analysis
Kaplan-Meier analyses were used to calculate DFS proba-
bilities. The log-rank test was used for DFS comparisons.
Patient disease characteristics and differences in amenor-
rhea rates were compared using the chi-square test. A p-
value < 0.05 was considered statistically significant.
Results
Patient characteristics
One hundred and fifty-four premenopausal patients were
included: 84 treated with 6FEC and 70 with 3FEC/3D.
Patient characteristics are described in Table 1. The
median age was 43.5 years (range: 28–58) in the 6FEC
arm and 44 years (range: 29–53) in the 3FEC/3D arm. The
classic prognostic factors for early breast cancer were also
well balanced between the two groups. Seventy-eight per-
cent of patients were treated in the context of the PACS 01
trial.BMC Cancer 2008, 8:56 http://www.biomedcentral.com/1471-2407/8/56
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Amenorrhea incidence
The incidence of chemotherapy-induced amenorrhea at
the end of treatment was not found to be statistically dif-
ferent between the two groups: 93 % in the 6 FEC arm and
92.5 % in the 3 FEC/3D arm (Table 2). However, in the
year following the end of chemotherapy, more patients
recovered regular menses in the 3FEC/3D arm than the
6FEC arm: 25 out of 70 (36.5 %) versus 20 out of 84 (23.7
%) (p < 0.019). Among the 101 patients for whom hor-
mone values were also available, more patients recovered
premenopausal hormone levels in the 3FEC/3D arm than
the 6FEC arm within a year after the end of chemotherapy
(42 % (18/42) versus 29 % (17/59)) (p < 0.01).
Premenopausal patients were also stratified according to
age (< or ≥ 40 years). The incidence of reversible chemo-
Design of the PACS 01 study Figure 1
Design of the PACS 01 study.BMC Cancer 2008, 8:56 http://www.biomedcentral.com/1471-2407/8/56
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therapy-induced amenorrhea was found to be similar
between the two chemotherapy regimens for patients
under 40 years of age (72 % (13/18) with 6FEC versus
71.4 % (15/21) with 3FEC/3D). For patients over 40 years
of age, however, statistically more recovered regular men-
ses in the 3FEC/3D arm than the 6FEC arm: 10 out of 49
(20 %) and 7 out of 66 (10.6 %) respectively (p < 0.025).
Clinically reversible amenorrhea and disease-free survival
At the time of analysis, the median follow-up for the
whole group was 79 months (96 months for 6FEC and 63
for 3FEC/3D). For the whole population, DFS was signif-
icantly better in patients with persistent amenorrhea after
one year compared to those who had recovered menses (p
= 0.0017) (data not shown). In the 6FEC group, there was
no statistical difference between patients with or without
persistent amenorrhea (p = 0.36). By contrast, in the
3FEC/3D group, there was a statistically significant advan-
Table 1: Patient characteristics
6 FEC 100 3 FEC/3D
Total number of patients (154) 84 70
Median age (range) 43.5 (28–58) 44 29–53)
Patients < 40 years (n = 39) 18 (21.5 %) 21 (30 %)
Patients ≥ 40 years (n = 115) 66 (78 %) 49 (70 %) (p = 0.08)
Hormone receptor status
Positive (ER and/or PR) 61 (72.6 %) 53 (75.9 %)
Negative (ER and PR) 23 (27.4 %) 17 (24.1 %)
ER positive 60 (71.4 %) 52 (74.2 %)
ER negative 24 (28.5 %) 18 (25.7 %)
PR positive 50 (59.5 %) 44 (62.8 %)
PR negative 34 (40.4 %) 26 (37.1 %)
Median tumor size (range)
Tumor grade
I 8 (9.5 %) 6 (8.6 %)
II 34 (40.5 %) 30 (42.8 %)
III 42 (50 %) 34 (48.6 %)
Number of metastatic lymph nodes
< 4 66 (78.6 %) 53 (75.9 %)
≥ 4 18 (21.4 %) 17 (24.1 %)
Tumor size
T1 25 (29.7 %) 21 (30 %)
T2 50 (59.5 %) 42 (60 %)
T3 9 (10.8 %) 7 (10 %)
ER: estrogen receptor; PR: progesterone receptor
(p-value never < 0.05)
Table 2: Incidence of amenorrhea
6FEC 100 3FEC/3D
Amenorrhea at the end of chemotherapy 78 (93 %) 65 (92.8 %)
Clinically reversible amenorrhea (n = 154)
Total population** 20/84 (23.7 %) 25/70 (35.5 %)
Patients < 40 years (39) 13/18 (72 %) 15/21 (71.4 %)
Patients ≥ 40 years (115)** 7/66 (10.5 %) 10/49 (20.5 %)
Recovery of premenopausal hormone values *
Total population (n = 101)** 18/59 (29 %) 18/42 (42 %)
Patients < 40 years (31) 11/15 (73.3 %) 12/16 (75 %)
Patients ≥ 40 years (70)** 6/42 (14 %) 6/28 (21.4 %)
Clinically reversible amenorrhea. No hormone values available (n = 53)
Patients < 40 years (8) 2/3 (66 %) 3/5 (60 %)
Patients ≥ 40 years (45)** 1/24 (4 %) 4/21 (19 %)
*within a year after the end of chemotherapy
** p < 0.05, chi-squareBMC Cancer 2008, 8:56 http://www.biomedcentral.com/1471-2407/8/56
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tage in DFS for patients who were still amenorrheic after
one year, compared to patients who had recovered regular
menses (p = 0.0001) (Figure 2).
When statistical analysis was restricted to patients whose
tumors expressed ER and/or PR, the same tendency was
observed in the 3FEC/3D group: a statistically significant
advantage for patients who were still amenorrheic after
one year, compared to those who had recovered premen-
opausal ovarian function (p < 0.002) (Figure 3). By con-
trast, in the 6FEC group, there was no statistical difference
between patients with or without persistent amenorrhea
(p = 0.22).
In the small subgroup of patients with ER- and PR-nega-
tive tumors, no statistically advantage in DFS was
observed in patients still amenorrheic at one year (p =
0.817 in the 6FEC arm and p = 0.445 in the 3FEC/3D
arm). But this subgroup was too small to allow valid sta-
tistical analysis.
Discussion
The rate of chemotherapy-related amenorrhea varies
according to the diagnostic criteria adopted and the dura-
tion of follow-up [1], but inconsistencies exist in the way
it is reported. Some authors report the incidence of amen-
orrhea immediately upon completion of chemotherapy,
while others select various time points after the start and
end of chemotherapy [1,5]. The time point most com-
monly encountered in the literature is 12 months after the
end of chemotherapy [2]. Chemotherapy-related amenor-
rhea is generally linked to the patient's age as well as treat-
ment protocol [1,2,7-9,11-13]. In our study, in women
over 40 years of age, reversible amenorrhea was more fre-
quently observed in patients treated with 3FEC/3D than
6FEC. Moreover, our data suggest that DFS was better in
patients with persistent amenorrhea in the 3FEC/3D
group.
Chemotherapy-related amenorrhea depends considerably
on the regimen used. Cyclophosphamide is a cytotoxic
agent that has been extensively investigated and is widely
known to induce amenorrhea [6,7]. According to Gol-
dhirsh [7], 61 % of women under 40 years of age experi-
enced amenorrhea after receiving CMF, while 95 % of
women over 40 became amenorrheic after this regimen.
Amenorrhea associated with anthracycline-based therapy
nevertheless shows significant variation from study to
study. Bines et al [1] found a 35 % amenorrhea rate with
the 4-cycle AC regimen (adriamycin 60 mg/m2, cyclo-
phosphamide 600 mg/m2, 4 courses every 3 weeks), Hor-
tobagyi et al [8] 59 % with the 6-cycle FAC regimen (5-
Kaplan Meier curves Figure 2
Kaplan Meier curves.BMC Cancer 2008, 8:56 http://www.biomedcentral.com/1471-2407/8/56
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fluorouracil 500 mg/m2, doxorubicin 50 mg/m2, cyclo-
phosphamide 500 mg/m2), and Levine et al [9] 51 % with
the 6-cycle CEF regimen (cyclophosphamide 75 mg/m2
orally on days 1 through 14, epirubicin 60 mg/m2 IV on
days 1 and 8, 5-fluorouracil 500 mg/m2 on days 1 and 8).
The results observed in our study with 6FEC 100 are not
different from those observed in the literature [1-3,8,9].
There are fewer published results on taxane regimens and
the are somewhat contradictory [11-13]. Moreover, some
of the literature is reported in abstract form [15-18]. In the
BCIRG 001 study [15,16,18], 6TAC was compared to
6FAC (TAC: docetaxel 75 mg/m2, doxorubicin 50 mg/m2,
cyclophosphamide 500 mg/m2; FAC: 5-fluorouracil 500
mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500
mg/m2). TAC gave better disease-free and overall survival
than FAC, but increased the rate of amenorrhea (66 % ver-
sus 54 %) (p = 0.008) by contrast, in our study, the 3 FEC/
3D regimen induced less definitive amenorrhea than the
6FEC 100 regimen. Unfortunately, the method and time
of evaluation of amenorrhea were not reported.
In the study by Fornier, 166 very young patients were
reviewed. All patients were treated with AC (doxorubicin
at a dose of 60 mg/m2 + cyclophosphamide at a dose of
600 mg/m2 for 4 cycles followed by a taxane). The major-
ity of patients were given AC followed by paclitaxel at a
dose of 175 mg/m2 for 4 cycles adminitered at 2- or 3-
week intertreatment intervals.
Only 7 patients received docetaxel (100 mg/m2).
In this cohort, long-term amenorrhea was defined as the
absence of menstruation ≥ 12 months after the comple-
tion of all chemotherapy. No hormone values were avail-
able and the conclusions of this study were that addition
Reversible amenorrhea and disease-free survival Figure 3
Reversible amenorrhea and disease-free survival.
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of a taxane did not appear to produce a higher rate of
chemotherapy-related amenorrhea, compared to histori-
cal controls.
In the study by Davis, 159 premenopausal patients were
reviewed. As initial chemotherapy, 102 women received
AC (doxorubicin/cyclophosphamide), 39 received CMF
(cyclophosphamide/methotrexate/5-fluorouracil) and 18
received CAF (cyclophosphamide/doxorubicin/5-fluor-
ouracil).
Following the initial regimen, 53 patients received addi-
tional adjuvant chemotherapy, generally with a taxane for
12 weeks (paclitaxel in 32 patients and docetaxel in 19
patients).
The conclusions of this study were similar to those of
Fornier. Sequential addition of taxanes did not appear to
increase the risk of chemotherapy-induced amenorrhea,
when added to non-taxane regimens. Moreover, the
author did not find any impact of the type of initial chem-
otherapy administered. The definition of chemotherapy-
related amenorrhea was the same as that used by Fornier
and our team. As in Fornier's study, no hormone values
were available.
More recently, Tham published a study involving 191
patients (158 patients ≤ 40 years of age at the start of
chemotherapy). The patients received 4 cycles of AC alone
or followed by a taxane (there was no stratification
between paclitaxel and docetaxel).
The definition of chemotherapy-related amenorrhea was
a little different in this study. Indeed, it was defined as ces-
sation of menses within 1 year of starting chemotherapy
and lasting ≥ 6 months.
As demonstrated in all these studies, age and type of
chemotherapy regimen were independently related to the
rate of chemotherapy-induced amenorrhea.
No hormone values were available.
In the subgroup of younger patients (≤ 40 years), addition
of a taxane resulted in a higher incidence of chemother-
apy-related amenorrhea (61 versus 44 %). In women over
40 years of age, amenorrhea rates were high in both the
group of AC alone and the group of AC followed by a tax-
ane (81 versus 85 %). No statistically significant differ-
ence was observed between the two groups.
However, in this study, the patients treated with a taxane
received more chemotherapy cycles and this could have
had an impact on the results.
In our study, women over 40 years of age were at much
greater risk of developing definitive amenorrhea than
those under 40, highlighting the importance of patient
age [19,20]. Milan's regimen, using 6 CMF with or with-
out doxorubicin, resulted in an amenorrhea rate of 4 % in
women under 30 years of age, 50 % in women aged
between 36 and 40 years, 86 % in women aged between
41 and 45 years, and 100 % in women over 45 years of age
[20]. Similar variations were observed with epirubicin-
containing regimens [8,9] and taxanes [11-13]. Our study
has the advantage of providing hormone profiles of 2/3 of
the patients, but the limitations are similar to those
encoutered, in other studies, i.e. the retrospective design
and the small number of patients.
Whether or not induction of amenorrhea by cytotoxic
chemotherapy is a prognostic factor in the treatment of
premenopausal women is still controversial. A positive
impact on DFS has been found by some [21-27], but not
confirmed by others [17,28]. Del Mastro et al [21] con-
ducted a review of 13 studies involving 3929 patients
undergoing CMF-based regimens, with follow-up ranging
from 3 to 20 years. A statistically significant association
was found between the development of chemotherapy-
related amenorrhea and DFS. In the majority of cases,
overall survival was found to be associated with amenor-
rhea (in 3 out of 5 studies reviewed). In a study recently
published by Parulekar [21], similar results were observed
with intensive CEF (cyclophosphamide, epirubicin, fluor-
ouracil) therapy, which induced a higher rate of amenor-
rhea than the classic CMF protocol, but overall survival
was also better.
Another important question relates to the duration of
amenorrhea. In Trial VI (study by the International Breast
Cancer Study Group (IBCSG)), cessation of menses, even
for a limited time period, appeared to be beneficial, espe-
cially in patients with ER-positive breast tumors. In this
study [29], however, the greatest effect was observed in
patients receiving suboptimal treatment with only three
initial CMF courses. In the PACS 01 trial [10], a survival
advantage in favor of the 3 FEC/3D arm was observed
only for women aged over 50 years, but not for the
younger population. The reason for this is unclear but the
impact of reversible amenorrhea in this context needs to
be investigated further, since our small retrospective anal-
ysis suggests that amenorrhea was correlated with DFS in
the 3FEC/3D group.
In our population, 73 % of patients received tamoxifen in
the 6FEC arm, and 74 % in the 3FEC/3D arm. The ovarian
stimulation effect of tamoxifen in premenopausal women
is well documented [30], but its effects on the duration of
chemotherapy-induced amenorrhea are not well defined
or understood. In a study by Tham [13], tamoxifen wasBMC Cancer 2008, 8:56 http://www.biomedcentral.com/1471-2407/8/56
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not shown to influence the incidence of amenorrhea, but
the impact of tamoxifen on the hypothalamo-pituitary
axis is complex and sequential administration of
tamoxifen after chemotherapy does not simplify the data.
It is therefore important to monitor a variety of hormonal
tests to assess the consequences of sequential administra-
tion of antiestrogen treatment after chemotherapy.
Gonadal toxicity resulting from chemotherapy was first
reported almost 60 years ago and the gonadotoxic effects
of chemotherapeutic agents are well documented.
Although the prevailing mechanisms are not fully under-
stood, three clinical studies have suggested that chemo-
therapy induces apoptotic changes in pregranulosa cells
that subsequently develop into follicles [31]. However,
these findings have not yet been confirmed in human
studies [3]. Chemotherapy also provokes a reduction in
the number of available oocytes. These changes are simi-
lar to those observed in natural postmenopausal ovaries.
This cytotoxic damage appears to be progressive and irre-
versible in the ovary, as jump cells are limited in number
and cannot be regenerated [32,33].
Conclusion
Our retrospective study confirms that chemotherapy-
related amenorrhea is highly complex, requiring in-depth
analysis, especially with the advent of new chemothera-
peutic agents. A number of questions need to be eluci-
dated in the coming years. Is achieving amenorrhea a
desirable side effect? Is temporary amenorrhea as effective
as definitive amenorrhea? What are the implications of
endocrine treatment for patients who recover ovarian
function? Is it necessary to propose ovarian function sup-
pression associated with tamoxifen or aromatase inhibi-
tors? Some of these questions are currently being
addressed in large randomized trials (PERCHE (stopped),
SOFT, TEXT). Besides the prognostic potential of reversi-
ble amenorrhea and therapeutic impact of the endocrine
approach, other issues also need clarification. What are
the implications of reversible amenorrhea on both sexual
function and preservation of fertility potential? All these
quesions are often a major concern for young premeno-
pausal breast cancer patients. On the basis of our findings,
we believe it is crucial to carefully monitor ovarian func-
tion after chemotherapy for at least 12 months following
the end of treatment, with separate analysis of results in
women with hormone-sensitive disease. The impact of
reversible amenorrhea on prognosis needs to be investi-
gated prospectively, and ovarian function followed clini-
cally, as well as by means of biochemical testing (large
randomized trials).
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